RECORDATI

RECORDATI, a Pharmaceutical Preparation Manufacturing company headquartered in Luxembourg, reported total carbon emissions of approximately 308.2 million kg CO2e in 2025. This includes about 36.6 million kg CO2e from Scope 1 emissions, 1.3 million kg CO2e from Scope 2 (market-based), and 270.3 million kg CO2e from Scope 3 emissions.

In 2024, RECORDATI's total carbon emissions were approximately 346.5 million kg CO2e, comprising about 37.3 million kg CO2e from Scope 1, 1.7 million kg CO2e from Scope 2 (market-based), and 307.5 million kg CO2e from Scope 3. The company has observed a decrease in total emissions between 2024 and 2025.

For 2023, RECORDATI reported Scope 1 emissions of approximately 36.6 million kg CO2e and Scope 2 market-based emissions of about 1.8 million kg CO2e. Full Scope 3 data for 2023 was not provided.

RECORDATI has set several climate commitments and targets:

• The company aims to reduce its Scope 1 emissions by 30% from a 2021 baseline by 2030.
• Similarly, it targets a 30% reduction in Scope 2 emissions from a 2021 baseline by 2030.
• By 2025, RECORDATI aims to achieve 100% renewable electricity purchased for its Group production and packaging sites and annexed offices (for both Scope 1 and Scope 2).
• RECORDATI, under the parent company Recordati Industria Chimica e Farmaceutica S.p.A., has Science Based Targets initiative (SBTi) approved near-term targets. These targets, approved using a streamlined validation route for Small and Medium-sized Enterprises (SMEs), commit to reducing Scope 1 and Scope 2 GHG emissions by 42% by 2030 from a 2023 base year, and to measure and reduce its Scope 3 emissions. These SBTi targets are consistent with reductions required to keep warming to 1.5°C.